Peng Yuan

Dr. Peng Yuan


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2024 in Phytomedicine
Verified
Journal Article
Closed access
JWJingyi Wei
Jingyi Wei
GLGuangyan Lei
Guangyan Lei
QCQiang Chen
Qiang Chen
WHWen Huang
Wen Huang
HNHui Ning
Hui Ning
PYPeng Yuan
Peng Yuan

4 January 2024 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
YCYafan Chen
Yafan Chen
ZHZhengyang Han
Zhengyang Han
LZLe Zhang
Le Zhang
CGCaihong Gao
Caihong Gao
JWJingyi Wei
Jingyi Wei
PYPeng Yuan
Peng Yuan
Background: Oral squamous cell carcinoma (OSCC), the predominant malignancy of the oral cavity, is characterized by high incidence and low survival rates. Emerging evidence suggests a link between circadian rhythm disruptions and cancer development. The circadian gene TIMELESS, known for its specific expression in various tumors, has not been extensively studied in the context of OSCC. This study aims to explore the influence of TIMELESS on OSCC, focusing on cell growth and metabolic alterations. Methods: We analyzed TIMELESS expression in OSCC using western blot, immunohistochemistry, qRT-PCR, and data from The Cancer Genome Atlas (TCGA) and the Cancer Cell Line Encyclopedia (CCLE). The role of TIMELESS in OSCC was examined through clone formation, MTS, cell cycle, and EdU assays, alongside subcutaneous tumor growth experiments in nude mice. We also assessed the metabolic impact of TIMELESS by measuring glucose uptake, lactate production, oxygen consumption, and medium pH, and investigated its effect on key metabolic proteins including silent information regulator 1 (SIRT1), hexokinase 2 (HK2), pyruvate kinase isozyme type M2 (PKM2), recombinant lactate dehydrogenase A (LDHA) and glucose transporter-1 (GLUT1). Results: Elevated TIMELESS expression in OSCC tissues and cell lines was observed, correlating with reduced patient survival. TIMELESS overexpression enhanced OSCC cell proliferation, increased glycolytic activity (glucose uptake and lactate production), and suppressed oxidative phosphorylation (evidenced by reduced oxygen consumption and altered pH levels). Conversely, TIMELESS knockdown inhibited these cellular and metabolic processes, an effect mirrored by manipulating SIRT1 levels. Additionally, SIRT1 was positively associated with TIMELESS expression. The expression of SIRT1, HK2, PKM2, LDHA and GLUT1 increased with the overexpression of TIMELESS levels and decreased with the knockdown of TIMELESS. Conclusion: TIMELESS exacerbates OSCC progression by modulating cellular proliferation and metabolic pathways, specifically by enhancing glycolysis and reducing oxidative phosphorylation, largely mediated through the SIRT1 pathway. This highlights TIMELESS as a potential target for OSCC therapeutic strategies.

25 November 2021 in Journal of Cell Communication and Signaling
Verified
Journal Article
Closed access
PDF file
JMJiao Mu
Jiao Mu
YTYiyuan Tian
Yiyuan Tian
FLFengzhou Liu
Fengzhou Liu
ZWZijun Wang
Zijun Wang
RTRui Tan
Rui Tan
PYPeng Yuan
Peng Yuan

6 June 2025 in Molecular Pain
Verified
Journal Article
Open access
JDJiaqi Dong
Jiaqi Dong
JWJingyi Wei
Jingyi Wei
HTHongwei Tong
Hongwei Tong
XSXiaohua Shi
Xiaohua Shi
MYMenghui Yuan
Menghui Yuan
JMJiao Mu
Jiao Mu
Pain, particularly chronic pain, is a major reason patients seek physical therapy. Inflammation plays a crucial role in both the development and persistence of chronic pain. Neuronal PAS domain protein 2 (NPAS2), a core circadian transcriptional regulator, has been implicated in modulating pain-related stress responses. In this study, we first examined NPAS2 expression in nociceptive-sensitized mice following complete Freund’s adjuvant (CFA) administration. We then systematically investigated the effects of CFA on astrocyte activation and inflammatory factor release in NPAS2 knockout (KO) mice. Our results demonstrated that NPAS2 deletion did not alter baseline pain thresholds under normal physiological conditions. However, in CFA-injected mice, NPAS2 KO significantly lowered mechanical and thermal pain thresholds in 50% of subjects, leading to enhanced nociceptive sensitization. This effect may be attributed to the promotion of astrocyte activation and the upregulation of pro-inflammatory cytokines, including IL-1β, IL-6, TNF-α, and NF-κB. These findings highlight NPAS2 as a potential prognostic biomarker for pain chronification and a promising therapeutic target for biologically tailored pain interventions.

19 September 2025 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
WHWen Huang
Wen Huang
ZHZhenghui Hou
Zhenghui Hou
YLYuxi Lin
Yuxi Lin
QBQianrong Bai
Qianrong Bai
MYMenghui Yuan
Menghui Yuan
PYPeng Yuan
Peng Yuan
This article presents a rare case of renal metastasis from papillary thyroid carcinoma (PTC) with concurrent lung and bone metastases. Through a retrospective analysis of the patient’s diagnostic and treatment process, we aim to contribute to the development of precise treatment strategies for such rare cases, thereby improving patient prognosis.

9 August 2025 in Future Oncology
Verified
Journal Article
Closed access
YLYunbo Li
Yunbo Li
JWJunyan Wang
Junyan Wang
JHJinzi Hui
Jinzi Hui
GHGuangdong Hou
Guangdong Hou
WHWei He
Wei He
MYMenghui Yuan
Menghui Yuan
This study aims to develop a comprehensive nomogram to accurately predict differentiated thyroid cancer (DTC) involved lymph node, enabling the personalization of treatment plans and optimizing patient outcomes. The nomogram was developed through an analysis of data obtained from derivation cohorts. To identify independent predictors of involved lymph node, we utilized the Least Absolute Shrinkage and Selection Operator (LASSO) method in conjunction with multivariable logistic regression. These predictive factors were subsequently integrated into the nomogram's design. To ensure the tool's robustness and clinical applicability, we assessed its discriminative ability, calibration, and clinical utility in both the derivation cohort and an independent validation cohort. The identification of four key parameters - Thyroglobulin, Lymphocyte count, BRAFV600E, and the number of tumor foci - emerged as robust predictors of involved lymph node. The nomogram demonstrated outstanding performance across calibration, discrimination, and clinical applicability, with predictive accuracies of 0.992 in the derivation cohort and 0.920 in the validation cohort. Peripheral lymphocyte counts have been found to correlate with involved lymph node in DTC patients. A nomogram tailored specifically for predicting involved lymph node in DTC guides personalized postoperative radioactive iodine (RAI) and plays a critical role in the preoperative assessment.